The administration of autologous pDCs, activated and pulsed with tumor antigens (gp100, tyrosinase), induces a systemic type I IFN response accompanied by the migration of pDCs in draining lymph nodes and triggering of antigen-specific CD4 and CD8 T-cells in patients with metastatic melanoma [55]. The gene discussed is PMEL; the disease is neoplasm.